MDA

Amylyx Pharmaceuticals to Present Updates on its AMX0114 and RELYVRIO® Programs in ALS at the 2024 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference

Retrieved on: 
Thursday, February 15, 2024
Biotechnology, Pharmaceutical, Health, Neurology, Steps, ALS, Vance DeGeneres, Conference, Safety, Muscular Dystrophy Association, AMX0035, Pharmacokinetics, Abstract, Amylyx Pharmaceuticals, PB, Medication, MDA, Axon, Episcopal conference, Pharmaceutical industry

AMX0035 is marketed by Amylyx as RELYVRIO® and is approved to treat ALS in adults in the U.S. and approved with conditions as ALBRIOZA™ for the treatment of ALS in Canada.

Key Points: 
  • AMX0035 is marketed by Amylyx as RELYVRIO® and is approved to treat ALS in adults in the U.S. and approved with conditions as ALBRIOZA™ for the treatment of ALS in Canada.
  • This poster shares details on pre-clinical efficacy studies as well as introduces the design approach for the first-in-human study, anticipated to begin later this year.
  • The Company is studying multiple cellular pathways implicated in disease pathogenesis as we believe that it is going to take a combination approach to find a cure for ALS.
  • Additional information, including copies of the poster presentations, will be made available on the “ Publications ” tab of the Amylyx website, following the conclusion of the poster presentations.

US Department of Defense Launches L3Harris Missile Tracking Satellites

Retrieved on: 
Thursday, February 15, 2024
Other Manufacturing, Technology, Other Defense, Contracts, Engineering, Satellite, Aerospace, Manufacturing, Government Technology, Defense, Architecture, Missile defense, Human, Ballistics, Work, Orbit, LHX, L3Harris Technologies, MDA, SDA

Five missile tracking satellites L3Harris Technologies (NYSE:LHX) designed and built successfully launched from Cape Canaveral Space Force Station, Florida, as part of the Missile Defense Agency’s (MDA) Hypersonic and Ballistic Tracking Space Sensor (HBTSS) program and the Space Development Agency’s (SDA) Tranche 0 (T0) Tracking Layer program.

Key Points: 
  • Five missile tracking satellites L3Harris Technologies (NYSE:LHX) designed and built successfully launched from Cape Canaveral Space Force Station, Florida, as part of the Missile Defense Agency’s (MDA) Hypersonic and Ballistic Tracking Space Sensor (HBTSS) program and the Space Development Agency’s (SDA) Tranche 0 (T0) Tracking Layer program.
  • The other four infrared satellites will support SDA’s Tracking Layer, which will demonstrate global indications, warning, tracking and targeting of advanced threats such as hypersonic missiles.
  • “L3Harris delivered this advanced missile tracking capability on behalf of MDA and SDA on orbit in just over three years after work was authorized to proceed.
  • We are proud to be a critical part of the new space sensing architecture.”
    This combined launch also supports SDA’s Proliferated Warfighter Space Architecture by integrating missile tracking and missile defense sensors.

Dyne Therapeutics Announces Upcoming Presentations on Initial Clinical Data From its ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference

Retrieved on: 
Wednesday, February 14, 2024
Therapy, Nationwide, Principal, DYN, DMD, Duchenne muscular dystrophy, Conference, DM1, Gene therapy, Safety, Muscular Dystrophy Association, Patient, MPH, Asian literature, PMO, Myopathy, MDA, Episcopal conference, Pharmaceutical industry

WALTHAM, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced two oral presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 3-6, 2024, in Orlando, Florida and virtually.

Key Points: 
  • Both presentations will highlight the initial clinical data from the ACHIEVE and DELIVER trials reported by Dyne in January 2024.
  • The initial clinical data from the ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) includes 6-month data from the 1.8 mg/kg (approximate ASO dose) cohort (n=16) and 3-month data from the 3.4 mg/kg Q4W cohort (n=16).
  • Initial 6-month clinical data from the 5 mg/kg (approximate PMO dose) cohort (n=6) of the DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping will also be presented.
  • Additionally, both presentations will include safety data from multiple cohorts in ACHIEVE and DELIVER trials which was shared in January.

MDA ANNOUNCES APPOINTMENT OF YUNG WU TO BOARD OF DIRECTORS

Retrieved on: 
Wednesday, February 14, 2024
National Association, Racism, Coalition, Computer science, Entrepreneurship, Indigenous peoples, TSX, Growth, NACD, YPO, MENSA, University, Mathematics, Black, Economics, MDA, Young Presidents' Organization, Corporation, Management

BRAMPTON, ON, Feb. 14, 2024 /PRNewswire/ - MDA Ltd. (TSX: MDA), a trusted space mission partner to the rapidly expanding global space industry, is pleased to announce the appointment of Yung Wu to MDA's Board of Directors, effective February 14, 2024.

Key Points: 
  • BRAMPTON, ON, Feb. 14, 2024 /PRNewswire/ - MDA Ltd. (TSX: MDA), a trusted space mission partner to the rapidly expanding global space industry, is pleased to announce the appointment of Yung Wu to MDA's Board of Directors, effective February 14, 2024.
  • Serving as an independent director, Mr. Wu's appointment increases the size of the Board to nine directors, in accordance with MDA's by-laws.
  • "We are pleased to welcome Yung Wu to our Board of Directors," said Mr. John Risley, Chair of the MDA Board.
  • He is also a member of MENSA, the Young Presidents Organization (YPO) and the Institute of Corporate Directors (ICD.D) and the National Association of Corporate Directors (NACD).

MDA AWARDED CONTRACT FROM GENERAL ATOMICS AERONAUTICAL SYSTEMS TO SUPPORT MQ-9B SKYGUARDIAN REMOTELY PILOTED AIRCRAFT SYSTEMS FOR THE GOVERNMENT OF CANADA

Retrieved on: 
Tuesday, February 13, 2024
Aircraft, RPAS, General Atomics Aeronautical Systems, Weather, TSX, Aircraft systems, FVEY, MDA

As part of the contract announced today, MDA will complete the assembly of the RPAS ground control stations at MDA's Richmond, BC, facility.

Key Points: 
  • As part of the contract announced today, MDA will complete the assembly of the RPAS ground control stations at MDA's Richmond, BC, facility.
  • MDA will also deliver the combat search and rescue radios for the program and design the RPAS Ground Control Centre information management system that controls how information flows, is secured and shared.
  • We are proud of our long, successful, and rich history of innovation with Canada and our Canadian partners.
  • We look forward to a long and fruitful collaboration with MDA Ltd."
    The GA-ASI contract will be added to MDA's backlog in the first quarter of fiscal 2024.

Muscular Dystrophy Association Announces Seven Recipient Organizations of Advocacy Collaboration Grants

Retrieved on: 
Thursday, February 1, 2024
Policy, Occupancy, CFO, Hospital, Neuromuscular disease, Travel, Wheelchair, MDA, Therapy, Muscular Dystrophy Association, Muscular dystrophy, Caregiver, Child, Safety, Patient, CMD, Atmosphere, Cure Rare Disease, Disease, Public policy, Air travel, NMD, VCP, DMD, Empowerment, Organization, Nursing

“Muscular Dystrophy Association is proud to announce the recipients of the MDA Advocacy Collaboration Grants.

Key Points: 
  • “Muscular Dystrophy Association is proud to announce the recipients of the MDA Advocacy Collaboration Grants.
  • “The Child Neurology Foundation is thrilled to be a recipient of Muscular Dystrophy Association’s Advocacy Collaboration Grants program to support the development of a comprehensive Needs Assessment Survey,” said Katie Hentges, Director of Programs.
  • “The Muscular Dystrophy Association Advocacy Collaboration Grant will enable Cure CMD to continue its legislative advocacy work and provide skills training, resources, and advocacy opportunities for the CMD community,” said Lani Knutson, Cure CMD Advocacy Team Lead.
  • Other innovative programs, campaigns, or initiatives that can measurably impact one or more of MDA and the collaborating organizations’ common advocacy goals.

Northrop Grumman Passes Preliminary Design Review for Next Generation Interceptor Solution

Retrieved on: 
Wednesday, January 31, 2024
Partnership, PDR, Raytheon Technologies, NGI, MDA, GMD, Missile Defense Agency, Intercontinental ballistic missile, Design review (U.S. government), NOC, Northrop Grumman, Credit, Next Generation, RTX, Grumman, ICBM, Arms industry

HUNTSVILLE, Ala., Jan. 31, 2024 (GLOBE NEWSWIRE) -- The Northrop Grumman Corporation (NYSE: NOC) Next Generation Interceptor team completed its All-Up Round (AUR) Preliminary Design Review (PDR), in partnership with the Missile Defense Agency (MDA) on January 26.

Key Points: 
  • HUNTSVILLE, Ala., Jan. 31, 2024 (GLOBE NEWSWIRE) -- The Northrop Grumman Corporation (NYSE: NOC) Next Generation Interceptor team completed its All-Up Round (AUR) Preliminary Design Review (PDR), in partnership with the Missile Defense Agency (MDA) on January 26.
  • Northrop Grumman’s Next Generation Interceptor (NGI) team completed its Preliminary Design Review one year earlier than the original contract date.
  • (Credit: Northrop Grumman)
    The PDR established the technical approach for the full integration of Northrop Grumman’s interceptor design across all its subsystems to move into more advanced phases of development.
  • Lisa Brown, vice president, Next Generation Interceptor program, Northrop Grumman: “The Northrop Grumman NGI PDR demonstrated our technology, innovation, readiness, and performance.

Muscular Dystrophy Association Announces Recipient of 2024 MDA Legacy Award for Achievement in Research, is Jeffrey Chamberlain, Ph.D., Leading Professor in Gene Therapy

Retrieved on: 
Tuesday, January 30, 2024
Vivisection, Muscular dystrophy, Hospital, Neuromuscular disease, Immune system, Episcopal conference, MDA, MD, Muscular Dystrophy Association, Patient, Reward, AAV, Protein, Regenerative medicine, DMD, Duchenne muscular dystrophy, Doctor of Philosophy, University, Conference, Vaccine

The award will be presented at the 2024 MDA Clinical & Scientific Conference on Monday, March 4, by Louis Kunkel, PhD , of Boston Children’s Hospital.

Key Points: 
  • The award will be presented at the 2024 MDA Clinical & Scientific Conference on Monday, March 4, by Louis Kunkel, PhD , of Boston Children’s Hospital.
  • The MDA Legacy Award for Achievement in Research is an annual recognition for outstanding accomplishments in neuromuscular disease research.
  • "The Muscular Dystrophy Association is elated to celebrate Dr. Chamberlain and honor him with the 2024 MDA Legacy Award for Achievement in Research for his achievements in translational research.
  • The previous recipient of the MDA Legacy Award for Achievement in Research in 2023 was Merit Cudkowicz, MD, MSC Massachusetts General Hospital, for her achievements in clinical research.

Muscular Dystrophy Association Opens Registration for Campers and Volunteers for MDA Summer Camp 2024 to be Held at Locations Nationwide

Retrieved on: 
Monday, January 22, 2024
Life, Volunteering, Muscular Dystrophy Association, Harley-Davidson, Community engagement, Muscular dystrophy, Biogen, General Motors, National Association, NALC, Neuromuscular disease, MDA, Creativity, Magic, Counselor, Summer camp, Tourism

New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the opening of registration for both campers and volunteers for its MDA Summer Camp program.

Key Points: 
  • New York, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today the opening of registration for both campers and volunteers for its MDA Summer Camp program.
  • MDA Summer Camp serves children and young adults ages 8 to 17 living with muscular dystrophy and related neuromuscular diseases.
  • Last summer, more than 800 campers attended MDA Summer Camp, with nearly 600 volunteers.
  • As is the case every year, MDA Summer Camp is offered on a first-come, first-served basis at no cost to participants.

Optimi Health Secures Amendment to Increase Quantities Of MDMA, MDA, And 2C-B Under Controlled Drugs And Substances Dealer’s Licence

Retrieved on: 
Friday, January 19, 2024
MDMA, DMF, Health, Part, Annual Review, Documentation, API, GMP, Communication, Food, Drug Master File, MDA, Health Canada, Ground substance, DEL, FRA

Effectively implemented on January 16, 2024, the amendment allows substantial increases in the quantities of MDMA, MDA, and 2CB under subsection J.01.059(4) of Part J of the Food and Drug Regulations.

Key Points: 
  • Effectively implemented on January 16, 2024, the amendment allows substantial increases in the quantities of MDMA, MDA, and 2CB under subsection J.01.059(4) of Part J of the Food and Drug Regulations.
  • Terms of the amendment now permit the following increases:
    N-METHYL-3,4-METHYLENEDIOXY AMPHETAMINE (MDMA) – from 2kg to 20kg.
  • It enhances our competitive advantage and perfectly aligns with our vision to be the leading global supplier of GMP MDMA and other psychedelic substances."
  • Optimi now has Health Canada approval to manufacture the following controlled substances: